Patents by Inventor Ann M. Lees
Ann M. Lees has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7807384Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: June 12, 2008Date of Patent: October 5, 2010Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20100028327Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: June 12, 2008Publication date: February 4, 2010Inventors: ANN M. LEES, ROBERT S. LEES, SIMON W. LAW, ANIBAL A. ARJONA
-
Patent number: 7402395Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: September 24, 2003Date of Patent: July 22, 2008Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Patent number: 7244410Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: July 9, 2003Date of Patent: July 17, 2007Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Patent number: 6878817Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: October 12, 2001Date of Patent: April 12, 2005Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20040040049Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: September 24, 2003Publication date: February 26, 2004Applicant: Boston Heart Foundation, Inc., a Massachusetts corporationInventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20040013668Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: July 9, 2003Publication date: January 22, 2004Applicant: Boston Heart Foundation, Inc., a Massachusetts corporationInventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Patent number: 6632923Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: July 14, 2000Date of Patent: October 14, 2003Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Patent number: 6605588Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: March 2, 2000Date of Patent: August 12, 2003Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20020194633Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: October 12, 2001Publication date: December 19, 2002Applicant: Boston Heart Foundation, Inc., a Massachusetts corporationInventors: Ann M. Lee, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20020152485Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: December 17, 2001Publication date: October 17, 2002Applicant: Boston Heart Foundation, Inc., a Massachusetts corporationInventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20020129388Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: December 17, 2001Publication date: September 12, 2002Applicant: Boston Heart Foundation, Inc., Massachusetts corporationInventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Publication number: 20020052033Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: ApplicationFiled: September 24, 2001Publication date: May 2, 2002Applicant: Boston Heart Foundation, Inc., a Massachusetts corporationInventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Patent number: 6355451Abstract: Isolated polynucleotides encoding novel polypeptides which are capable of binding to native and methylated LDL (low density lipoprotein), the isolated polypeptides, called LBPs (LDL binding proteins), and biologically active fragments and analogs thereof, are described. Also described are methods for determining if an animal is at risk for atherosclerosis, methods for evaluating an agent for use in treating atherosclerosis, methods for treating atherosclerosis, and methods for treating a cell having an abnormality in structure or metabolism of LBP. Pharmaceutical compositions and vaccine compositions are also provided.Type: GrantFiled: November 26, 1997Date of Patent: March 12, 2002Assignee: Boston Heart Foundation, Inc.Inventors: Ann M. Lees, Robert S. Lees, Simon W. Law, Anibal A. Arjona
-
Patent number: 5972890Abstract: Vascular disease including asymptomatic atherosclerosis can be diagnosed by administering a synthetic peptide or peptide analog having an affinity for, and propensity to accumulate at, a site of vascular injury to a patient, and then detecting the location of the peptide or peptide analog within the patient's vascular system. The synthetic peptide or peptide analog may include an amino acid sequence sufficiently duplicative of the amino acid sequence of a region of either the apolipoprotein B, apolipoprotein A-I, or elastin proteins such that the peptide or peptide analog accumulates at a site of vascular injury.Type: GrantFiled: February 28, 1995Date of Patent: October 26, 1999Assignee: New England Deaconess Hospital CorporationInventors: Robert S. Lees, Ann M. Lees, Allan Fischman, Ing-Lung Shih, Mark A. Findeis
-
Patent number: 5955055Abstract: Vascular disease including asymptomatic atherosclerosis can be diagnosed by administering a synthetic peptide or peptide analog having an affinity for, and propensity to accumulate at, a site of vascular injury to a patient, and then detecting the location of the peptide or peptide analog within the patient's vascular system. The synthetic peptide or peptide analog may include an amino acid sequence sufficiently duplicative of the amino acid sequence of a region of either the apolipoprotein B, apolipoprotein A-I, or elastin proteins such that the peptide or peptide analog accumulates at a site of vascular injury.Type: GrantFiled: June 6, 1995Date of Patent: September 21, 1999Assignee: New England Deaconess Hospital CorporationInventors: Robert S. Lees, Ann M. Lees, Allan Fischman, Ing-Lung Shih, Mark A. Findeis
-
Patent number: 5726153Abstract: Vascular disease including asymptomatic atherosclerosis can be diagnosed by administering a synthetic peptide or peptide analog having an affinity for, and propensity to accumulate at, a site of vascular injury to a patient, and then detecting the location of the peptide or peptide analog within the patient's vascular system. The synthetic peptide or peptide analog may include an amino acid sequence sufficiently duplicative of the amino acid sequence of a region of either the apolipoprotein B, apolipoprotein A-I, or elastin proteins such that the peptide or peptide analog accumulates at a site of vascular injury.Type: GrantFiled: June 6, 1995Date of Patent: March 10, 1998Assignee: New England Deaconess Hospital CorporationInventors: Robert S. Lees, Ann M. Lees, Allan Fischman, Ing-Lung Shih, Mark A. Findeis